Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.

ABSTRACT:

Background

Molecularly targeted therapies using receptor inhibitors, small molecules or monoclonal antibodies are routinely applied in oncology. Verification of target expression should be mandatory prior to initiation of therapy, yet, determining the expression status is most challenging in recurrent glioblastoma (GBM) where most patients are not eligible for second-line surgery. Because very little is known on the consistency of expression along the clinical course we here explored common drug targets in paired primary vs. recurrent GBM tissue samples.

Methods

Paired surgical tissue samples were derived from a homogeneously treated cohort of 34 GBM patients. All patients received radiotherapy and temozolomide chemotherapy. Verification of common drug targets included immun

SUBMITTER: Schafer N 

PROVIDER: S-EPMC6425567 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature